Log In
Print
BCIQ
Print
Print this Print this
 

inotuzumab ozogamicin (CMC-544, PF-5208773)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHumanized mAb against CD22 linked to the calicheamicin cytotoxin
Molecular Target CD22
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphocytic leukemia (ALL) in elderly patients
Regulatory Designation

U.S. - Orphan Drug (Treat acute lymphocytic leukemia (ALL) in elderly patients);
EU - Orphan Drug (Treat acute lymphocytic leukemia (ALL) in elderly patients)

Partner

UCB Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today